TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Increase in the Non-encouraged 6 Minute Walk Test From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Umbilical trocar site hernia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subjects' Assessment of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Improvement in Skin Laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment assessment using RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse events documented using NCI-CTC coding system
Endpoint domain: Adverse events/effects
Primary endpoint: Vasodilator response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent change in wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month Overall Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 1 year Overall Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Total intra-operative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Free association test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Success rate of silver nitrate pleurodesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of co-morbidities and multimorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in self-care
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changes in treatment adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Area Under the Curve-Serum T
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical parameters (nitric oxide and arginase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in decline of ALS-FRS(R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma PF-06651600 concentration (C max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative healing rate of erosive esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Headache Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Adverse Events of Special Interest: Cardiovascular Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Adverse Events of Special Interest: Decreased Bone Density
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Adverse Events of Special Interest: Glucose Intolerance or Type 2 Diabetes Mellitus (T2DM)
Endpoint domain: Adverse events/effects
Primary endpoint: Regional cerebral oxygen saturation measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression-Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in active shoulder range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cervical ripening success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary Biomarker Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Reduction in Number of Drop Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Sleep consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical toxicity (DLT and MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital Signs and Postoperative Analgesic Follow-up Form (VSPAFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of change in biomarkers during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline quality of life score at 8 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline quality of life score at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline quality of life score at 24 weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Manometry finding (peristaltic amplitude values mmHG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concordance rate between rectal cancer staging methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from MALE
Endpoint domain: Adverse events/effects
Primary endpoint: Composite clinical safety by freedom from adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Effect (Emax) of High Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emax of Any Effects VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emax of Drug Liking VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxidative markers (isoprostanes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster universities Osteoarthritis Index (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cognitive abilities screening instrument (CASI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Glia mediators of neuroinflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve from time zero to 28 hours after administration (AUC 0-28hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve from time zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed maximum serum concentration following drug administration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complete Cure: Post Treatment (Day 17)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Complete Cure: Post Treatment (Day 31)
Endpoint domain: Mortality/survival
Primary endpoint: Left ventricular ejection fraction (LVEF) at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: quantitative and functional changes in CD4, CD8, NK, and Treg populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: levels of cytokines and chemokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug (biologics) persistency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SDNN (standard deviation of NN-intervals)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving Sustained Virologic Response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: labor time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal Atrophy Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived degree of gastric complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Finishing time during 10 km running event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in isometric maximal knee flexor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cmax of Rebamipide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Rebamipide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Burden on the German Version of Zarit Caregiver Burden Interview (ZBI) at Month 6
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Burden on the German Version of Zarit Caregiver Burden Interview (ZBI) at Month 9
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: FEV0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Plasma Concentration Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity (Steps/Day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Positive Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Negative Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Forearm blood flow ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amount of anaesthetics during flexible bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Local response at 6 months after Proton Beam Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline subjective well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Monocular Refractive Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity at 20 Degree Downsize Angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a Posterior Vitreous Detachment (PVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence/frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive performance on Go/no-go task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance on Digit span task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance on Symmetry span task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance on Operation span task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance on Groton's Maze task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cmax: Maximum Observed Concentration of Alisertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(Last): Area Under the Plasma Concentration Curve From Time 0 to the Time of the Last Quantifiable Concentration of Alisertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞: Area Under the Plasma Concentration Curve From Time 0 to Infinity of Alisertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 24-hour Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Coagulation as Indicated by Number of Participants With Reported Venous Thrombolic Events (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Arterial stiffness as assessed by Pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial stiffness as assessed by Ambulatory Arterial Stiffness Index (AASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial stiffness as assessed by Augmentation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial function as assessed by Laser Doppler flow perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Blood pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality sex life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Female Sexual Function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Evaluation of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with adverse clinical outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in depth of wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in diameter of the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of moderate and severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Fibroblast Growth Factor 21 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient safety incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Change in disease assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in sexual disorders
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Cognitive function as measured by ADAS-Cog+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in pathological breathing events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Skin color assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Days Abstinent Per Month From Drug Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximum tolerated dose of radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor response following reirradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain intensity in the study joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in organ failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Absolute Oral Bioavailability (%F) for Mobocertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma and Whole Blood Concentration for Mobocertinib and Its Metabolites (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma and Whole Blood Concentration-time Curve From Time 0 to Infinity for Mobocertinib and Its Metabolites (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contralateral Diaphragm function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of Ad.hIFN-β
Endpoint domain: Adverse events/effects
Primary endpoint: Bone height changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Patients Achieving Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Viral Response (SVR) at Week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound finding of hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Withdrawn Due to Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Abnormalities for Clinical Chemistry Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disruptive Behavior Disorder Rating Scale (DBDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOWA Connors Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strengths and Difficulties Questionnaire (SDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ureteral Stent Symptoms Questionnaire (USSQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: C24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in tumor proliferation (Ki67)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in microvessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in phosphorylated VEGFR-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Metabolism of ornithine phenylacetate to glutamate and glutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MRI sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in the Caregiver Reaction Assessment (CRA) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absolute change in the scores for the assessment domains included in the Ben Rose Institute (BRI) care consultation program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of large volume paracentesis needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The volume of fluid removed in liters after high-dose albumin administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients prescribed antimalarial therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Health related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: High-Risk HPV DNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in severity of freezing of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the score of Gait and Fall Questionnaire (GFQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC after single dose of dexpramipexole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax after single dose of dexpramipexole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference From Baseline in the Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Genetic markers associated with treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penn Daily Symptom Report (DSR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Outcomes in scleroderma calcinosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator assessment of wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Blood pressure, heart rate, electrocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of at least one Grade 3 or higher adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immediate change in gait function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate change in cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in State Trait Anger Expression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MEQ scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Annualized Confirmed Relapse Rate (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes